The lead drug is a glutaminase inhibitor, targeting an enzyme that plays a role in tumor metabolism. The biotech plans to identify patient populations that will most benefit from the drug, sticking with a carefully targeted approach that has dominated the cancer drug field.
Susan Molineaux (photo) helped guide cancer drug developer Proteolix from early stage multiple myeloma research through Phase II trials. The developer was snapped up by Onyx Pharmaceuticals, which
South San Francisco-based startup Calithera Biosciences has banked a whopping $40 million Series A round to ramp up development work on a new group of cancer drugs discovered in the lab of James